Entry Point Capital, LLC Akero Therapeutics, Inc. Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
A detailed history of Entry Point Capital, LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 4,311 shares of AKRO stock, worth $117,862. This represents 0.15% of its overall portfolio holdings.
Number of Shares
4,311Holding current value
$117,862% of portfolio
0.15%Shares
2 transactions
Others Institutions Holding AKRO
# of Institutions
168Shares Held
72.7MCall Options Held
178KPut Options Held
164K-
Janus Henderson Group PLC London, X06.88MShares$188 Million0.09% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$153 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$149 Million2.13% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$143 Million3.88% of portfolio
-
Wellington Management Group LLP Boston, MA5.11MShares$140 Million0.02% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.27B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...